Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-05
DOI
10.3389/fonc.2022.955894
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis
- (2022) Alberto Martini et al. CANCER TREATMENT REVIEWS
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation
- (2021) Luigi Nocera et al. European Urology Focus
- Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
- (2021) Luigi Nocera et al. JOURNAL OF UROLOGY
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
- (2020) L. Albiges et al. ANNALS OF ONCOLOGY
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
- (2018) Christopher J.D. Wallis et al. EUROPEAN UROLOGY
- Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
- (2017) Kyongsun Pak et al. JAMA Oncology
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
- (2017) Dae Hyun Kim et al. JAMA Cardiology
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
- (2015) Hajime Uno et al. ANNALS OF INTERNAL MEDICINE
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research
- (2010) Susan Armijo-Olivo et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- SAS and R functions to compute pseudo-values for censored data regression
- (2008) John P. Klein et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started